Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2 Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated Cash Position: $75.3 million in Cash, Cash Equivalents, and Short-Term

PALO ALTO, Calif. , May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the

William G. Kachioff appointed as Chief Financial Officer James A. Vollins appointed as General Counsel, Chief Compliance Officer and Corporate Secretary PALO ALTO, Calif. , April 13, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company